BioSight

Company Overview

Snapshot

Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operated with 1–10 employees. The company raised $62.5M across 5 funding rounds from 9 investors. BioSight was acquired by Ayala Pharmaceuticals in October 2023.

Business overview

BioSight was a phase-2 clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. The company investigated BST-236 as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful phase-1/2a trial. BioSight operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the Pharmaceuticals market.

Strategic signal

In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the biotechnology firm. This acquisition signals a consolidation within the oncology therapeutics market and indicates the strategic value placed on BioSight's clinical-stage assets, particularly its lead product BST-236, by larger pharmaceutical entities.

Company Intelligence Q&A

What was BioSight's most significant corporate event?

BioSight was acquired by Ayala Pharmaceuticals in October 2023, leading to its inactive status.

What is BioSight's primary therapeutic focus?

BioSight focused on developing therapeutics for hematological malignancies and disorders, with its lead product, BST-236, targeting acute myeloid leukemia (AML).

When did BioSight secure its last disclosed funding round?

In December 2020, BioSight closed a Series C financing round. Investors included Israel Biotech Fund and Arkin Bio.

Did BioSight receive any special designations for its lead product?

In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of acute myeloid leukemia. Additionally, in June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the same indication.

What was the status of BioSight's clinical trials for BST-236?

In November 2022, BioSight launched a Phase 1/2 clinical trial of Aspacytarabine (BST-236) in combination with Venetoclax for first-line AML induction therapy, followed by Aspacytarabine consolidation.